Postoperative Nausea and Vomiting (PONV) Market, Global Outlook and Forecast 2023-2030

Transparency Market Research (TMR) has published a new report titled, “Post-operative Nausea and Vomiting (PONV) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, in June 2018.

Increase in patient population experiencing post-operative nausea and vomiting, rise in adoption rate of combination therapies as well as non-pharmacological treatment modes, surge in funding, and launch of newer therapies are expected to boost the growth of the post-operative nausea and vomiting (PONV) during the forecast period from 2018 to 2026.

This can be ascribed to large patient population, rise in chronic diseases requiring surgical intervention in countries such as China and Japan, and various initiatives undertaken by the government and non-profit organizations to promote awareness about the treatment of post-operative complications.

However, the incidence rate can increase to nearly 80% in patients with multiple risk factors for PONV, if antiemetic prophylaxis is not appropriate.TOC of Report – https://www.transparencymarketresearch.com/report-toc/2969 Demand for combination drugs is rising among different classes, with various mechanism of actions for use in patients with moderate to high risk for PONV.

Large number of clinical practice organizations also advocate usage of prophylactic antiemetic combinations.

PONV is caused by multiple factors, and therefore, demand for combination antiemetic therapy among patients is high.

The exclusive research report on the Global Postoperative Nausea and Vomiting Treatment Market 2021 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market.

Global Postoperative Nausea and Vomiting Treatment Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.Overview of Global Postoperative Nausea and Vomiting Treatment Market:The report spread across 350 pages is an overview of the Global Postoperative Nausea and Vomiting Treatment Market Report 2021.

The analytical examination is proposed to give immense clarity on the market size, share and growth rate crosswise over various regions.

The significant information and broad examination of the patterns from the days of old and future goes for offering the stakeholders, product owners, and marketing work force an aggressive edge over others working in the Postoperative Nausea and Vomiting Treatment Market for the figure forecast period 2020 – 2025.The Global Postoperative Nausea and Vomiting Treatment Market is expected to grow at a CAGR of 13.20% in the forecast period of 2021 to 2028.Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-postoperative-nausea-and-vomiting-treatment-market .According to the market report analysis, Postoperative Nausea and Vomiting (PONV) is used to describe nausea and vomiting or retching in the post-anesthesia care unit (PACU).

The consequences of PONV include increased anxiety for future surgical procedures, more time consumption in recovery, hospital stay and some other severe consequences such as aspiration pneumonia, metabolic alkalosis, and surgical complications.The most important key factors driving the growth of the Global Postoperative Nausea and Vomiting Treatment Market are increase in the prevalence of postoperative nausea and vomiting complications, growing demand for combination therapy, rise in the number of surgeries as a treatment option, rise in healthcare expenditure and growing government initiatives for spreading awareness.The Global Postoperative Nausea and Vomiting Treatment Market is segmented on the basis of Treatment Type, Application and End-User.

On the basis of Treatment Type, the Postoperative Nausea and Vomiting Treatment Market is segmented into serotonin receptor antagonists, steroids, dopamine antagonists, neurokinin NK-1 receptor antagonists, and non-pharmacological treatment.

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments.

Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others.

The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others.

The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58According to this study, over the next five years the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market will register a 5.9% CAGR in terms of revenue, the global market size will reach US$ 96 million by 2024, from US$ 72 million in 2019.

In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business, shared in Chapter 3.This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.This study considers the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs value and volume generated from the sales of the following segments:Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.5-HT3 InhibitorsNK1 InhibitorsOtherSegmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.Highly Emetogenic ChemotherapyModerately Emetogenic ChemotherapyLow Emetogenic ChemotherapyOtherThis report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaSpainMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC CountriesThe report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

The key manufacturers covered in this report: Breakdown data in in Chapter 3.MerckEisaiMundipharmaQilu PharmaTevaNovartisHeron TherapeuticsRocheMylanTesaroResearch objectives:To study and analyze the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by identifying its various subsegments.Focuses on the key global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapy-induced-nausea-vomiting-drugs-2019-2024-58Table of content1 Scope of the Report1.1 Market Introduction1.2 Research Objectives1.3 Years Considered1.4 Market Research Methodology1.5 Economic Indicators1.6 Currency Considered2 Executive Summary2.1 World Market Overview2.1.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption 2014–20242.1.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption CAGR by Region2.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Type2.2.1 5-HT3 Inhibitors2.2.2 NK1 Inhibitors2.2.3 Other2.3 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption by Type2.3.1 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Consumption Market Share by Type (2014–2019)2.3.2 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Revenue and Market Share by Type (2014–2019)2.3.3 Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sale Price by Type (2014–2019)2.4 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Segment by Application2.4.1 Highly Emetogenic ChemotherapyCONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/